The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
Adult
Aged
Anti-Bacterial Agents
/ pharmacology
Azabicyclo Compounds
/ pharmacology
Bacterial Proteins
/ genetics
Carbapenems
/ pharmacology
Ceftazidime
/ pharmacology
Cephalosporins
/ pharmacology
Drug Combinations
Drug Resistance, Bacterial
Epidemiological Monitoring
Female
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Pseudomonas Infections
/ microbiology
Pseudomonas aeruginosa
/ drug effects
Young Adult
beta-Lactamases
/ genetics
Carbapenem-resistant P. aeruginosa
Carbapenemase
Ceftazidime/avibactam
Ceftolozane/tazobactam
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
24
05
2021
accepted:
07
07
2021
pubmed:
23
7
2021
medline:
22
12
2021
entrez:
22
7
2021
Statut:
ppublish
Résumé
The cephalosporin-β-lactamase-inhibitor-combinations, ceftolozane/tazobactam and ceftazidime/avibactam, have revolutionized treatment of carbapenem-resistant Pseudomonas aeruginosa (CR-PA). A contemporary assessment of their in vitro potency against a global CR-PA collection and an assessment of carbapenemase diversity are warranted. Isolates determined as CR-PA by the submitting site were collected from 2019-2021 (17 centers in 12 countries) during the ERACE-PA Global Surveillance Program. Broth microdilution MICs were assessed per CLSI standards for ceftolozane/tazobactam, ceftazidime/avibactam, ceftazidime, and cefepime. Phenotypic carbapenemase testing was conducted (modified carbapenem inactivation method (mCIM)). mCIM positive isolates underwent genotypic carbapenemase testing using the CarbaR, the CarbaR NxG, or whole genome sequencing. The MIC
Identifiants
pubmed: 34291323
doi: 10.1007/s10096-021-04308-0
pii: 10.1007/s10096-021-04308-0
pmc: PMC8590662
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azabicyclo Compounds
0
Bacterial Proteins
0
Carbapenems
0
Cephalosporins
0
Drug Combinations
0
avibactam, ceftazidime drug combination
0
ceftolozane
37A4IES95Q
Ceftazidime
9M416Z9QNR
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2533-2541Informations de copyright
© 2021. The Author(s).
Références
Crit Care Med. 2012 Apr;40(4):1329-32
pubmed: 22425824
Clin Microbiol Rev. 2013 Jul;26(3):361-80
pubmed: 23824364
Int J Infect Dis. 2017 Sep;62:39-43
pubmed: 28610832
J Clin Microbiol. 2018 Oct 25;56(11):
pubmed: 30158194
J Antimicrob Chemother. 2019 Jul 1;74(7):1934-1939
pubmed: 31225611
Antimicrob Agents Chemother. 2006 May;50(5):1633-41
pubmed: 16641429
Antibiotics (Basel). 2020 Oct 27;9(11):
pubmed: 33120865
J Clin Microbiol. 2020 Nov 18;58(12):
pubmed: 33115845
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32238433
mSphere. 2021 Jan 27;6(1):
pubmed: 33504661
J Clin Microbiol. 2017 Dec 26;56(1):
pubmed: 29070655
Clin Infect Dis. 2016 Jul 15;63(2):234-41
pubmed: 27098166
Antimicrob Agents Chemother. 2015 Dec 07;60(2):1067-78
pubmed: 26643349
J Antimicrob Chemother. 2019 Dec 1;74(12):3497-3504
pubmed: 31504587
Clin Microbiol Rev. 2020 Feb 26;33(2):
pubmed: 32102899
J Antimicrob Chemother. 2017 May 1;72(5):1386-1395
pubmed: 28165526
Lancet Infect Dis. 2016 Jun;16(6):661-673
pubmed: 27107460
Antibiotics (Basel). 2020 Feb 09;9(2):
pubmed: 32050434
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4743-9
pubmed: 27216074
Open Forum Infect Dis. 2019 Jun 06;6(7):ofz273
pubmed: 31281867
Braz J Infect Dis. 2017 Nov - Dec;21(6):627-637
pubmed: 28941394
Int J Antimicrob Agents. 2015 Jun;45(6):568-85
pubmed: 25857949
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28739780
Clin Microbiol Rev. 2019 Aug 28;32(4):
pubmed: 31462403
Clin Infect Dis. 2020 Jul 11;71(2):304-310
pubmed: 31545346